Two-Arm, Randomized, Open-Label, Phase IIIb Study Investigating the Safety of a 3 Hour i.p. Infusion of Catumaxomab With and Without Prednisolone Premedication in Patients With Malignant Ascites Due to Epithelial Cancer.

Trial Profile

Two-Arm, Randomized, Open-Label, Phase IIIb Study Investigating the Safety of a 3 Hour i.p. Infusion of Catumaxomab With and Without Prednisolone Premedication in Patients With Malignant Ascites Due to Epithelial Cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Dec 2016

At a glance

  • Drugs Catumaxomab (Primary) ; Prednisolone (Primary)
  • Indications Malignant ascites
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms CASIMAS
  • Sponsors Neovii Biotech
  • Most Recent Events

    • 01 Oct 2012 Quality-of-life results presented at the 37th Congress of the European Society for Medical Oncology.
    • 30 Sep 2012 Primary endpoint results presented at the 37th Congress of the European Society for Medical Oncology.
    • 23 Jun 2012 Additional locations added as reported by European Clinical Trials Database
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top